Barclays’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.4M | Buy |
40,800
+30,000
| +278% | +$10.7M | ﹤0.01% | 1253 |
|
|
2025
Q4 | $3.53M | Sell |
10,800
-14,700
| -58% | -$4.66M | ﹤0.01% | 2492 |
|
|
2025
Q3 | $7.2M | Sell |
25,500
-404,800
| -94% | -$117M | ﹤0.01% | 1931 |
|
|
2025
Q2 | $120M | Buy |
430,300
+264,700
| +160% | +$75M | 0.03% | 407 |
|
|
2025
Q1 | $51.6M | Buy |
165,600
+113,900
| +220% | +$33.6M | 0.01% | 647 |
|
|
2024
Q4 | $13.5M | Sell |
51,700
-299,600
| -85% | -$88.9M | ﹤0.01% | 1348 |
|
|
2024
Q3 | $113M | Buy |
+351,300
| New | +$115M | 0.03% | 391 |
|
|
2024
Q2 | – | Sell |
-432,400
| Closed | -$123M | – | 4839 |
|
|
2024
Q1 | $123M | Buy |
432,400
+170,800
| +65% | +$50M | 0.04% | 335 |
|
|
2023
Q4 | $75.3M | Sell |
261,600
-178,200
| -41% | -$48.6M | 0.03% | 509 |
|
|
2023
Q3 | $118M | Buy |
439,800
+254,800
| +138% | +$63.6M | 0.07% | 258 |
|
|
2023
Q2 | $41.1M | Sell |
185,000
-10,600
| -5% | -$2.46M | 0.03% | 508 |
|
|
2023
Q1 | $47.3M | Buy |
195,600
+161,000
| +465% | +$39.5M | 0.02% | 485 |
|
|
2022
Q4 | $9.09M | Buy |
+34,600
| New | +$9.27M | ﹤0.01% | 1249 |
|
|
2021
Q3 | – | Sell |
-28,400
| Closed | -$6.92M | – | 4732 |
|
|
2021
Q2 | $6.92M | Buy |
28,400
+8,400
| +42% | +$2.07M | ﹤0.01% | 1404 |
|
|
2021
Q1 | $4.98M | Sell |
20,000
-35,500
| -64% | -$8.47M | ﹤0.01% | 1521 |
|
|
2020
Q4 | $12.8M | Buy |
55,500
+9,700
| +21% | +$2.24M | 0.01% | 1051 |
|
|
2020
Q3 | $11.6M | Hold |
45,800
| – | – | 0.01% | 971 |
|
|
2020
Q2 | $10.8M | Sell |
45,800
-12,500
| -21% | -$2.85M | 0.01% | 922 |
|
|
2020
Q1 | $11.8M | Sell |
58,300
-170,200
| -74% | -$37.2M | 0.01% | 906 |
|
|
2019
Q4 | $55.1M | Buy |
228,500
+8,300
| +4% | +$1.83M | 0.03% | 470 |
|
|
2019
Q3 | $42.6M | Sell |
220,200
-249,400
| -53% | -$47.9M | 0.03% | 525 |
|
|
2019
Q2 | $86.5M | Buy |
469,600
+85,500
| +22% | +$15.3M | 0.05% | 310 |
|
|
2019
Q1 | $73M | Buy |
384,100
+97,700
| +34% | +$18.7M | 0.05% | 328 |
|
|
2018
Q4 | $55.8M | Buy |
286,400
+93,100
| +48% | +$18.2M | 0.04% | 346 |
|
|
2018
Q3 | $40.1M | Buy |
193,300
+14,700
| +8% | +$2.9M | 0.03% | 505 |
|
|
2018
Q2 | $33M | Sell |
178,600
-62,900
| -26% | -$11.1M | 0.03% | 537 |
|
|
2018
Q1 | $41.2M | Buy |
241,500
+98,400
| +69% | +$18.1M | 0.03% | 500 |
|
|
2017
Q4 | $24.9M | Buy |
143,100
+21,500
| +18% | +$3.8M | 0.02% | 695 |
|
|
2017
Q3 | $22.7M | Sell |
121,600
-67,900
| -36% | -$12M | 0.02% | 609 |
|
|
2017
Q2 | $32.6M | Sell |
189,500
-12,000
| -6% | -$1.95M | 0.04% | 406 |
|
|
2017
Q1 | $33.1M | Sell |
201,500
-4,700
| -2% | -$781K | 0.04% | 371 |
|
|
2016
Q4 | $30.1M | Buy |
206,200
+34,800
| +20% | +$5.24M | 0.03% | 425 |
|
|
2016
Q3 | $28.6M | Buy |
171,400
+8,800
| +5% | +$1.49M | 0.03% | 411 |
|
|
2016
Q2 | $24.7M | Buy |
162,600
+15,000
| +10% | +$2.33M | 0.03% | 438 |
|
|
2016
Q1 | $22M | Buy |
147,600
+64,500
| +78% | +$9.58M | 0.03% | 439 |
|
|
2015
Q4 | $13.5M | Sell |
83,100
-119,200
| -59% | -$18.7M | 0.02% | 746 |
|
|
2015
Q3 | $27.9M | Sell |
202,300
-183,700
| -48% | -$29M | 0.03% | 449 |
|
|
2015
Q2 | $59.1M | Buy |
386,000
+13,700
| +4% | +$2.19M | 0.07% | 246 |
|
|
2015
Q1 | $59.2M | Sell |
372,300
-27,700
| -7% | -$4.36M | 0.07% | 267 |
|
|
2014
Q4 | $63.6M | Sell |
400,000
-105,500
| -21% | -$16.4M | 0.06% | 264 |
|
|
2014
Q3 | $70.8M | Buy |
505,500
+75,300
| +18% | +$9.83M | 0.07% | 236 |
|
|
2014
Q2 | $50.8M | Buy |
430,200
+191,500
| +80% | +$22.2M | 0.05% | 305 |
|
|
2014
Q1 | $29.4M | Sell |
238,700
-307,000
| -56% | -$37.2M | 0.03% | 496 |
|
|
2013
Q4 | $62.2M | Buy |
545,700
+131,600
| +32% | +$15M | 0.06% | 270 |
|
|
2013
Q3 | $46M | Buy |
414,100
+164,200
| +66% | +$17.8M | 0.05% | 322 |
|
|
2013
Q2 | $24.7M | Buy |
+249,900
| New | +$25.9M | 0.03% | 550 |
|
Other funds holding AMGN
VCM
VPM
Barclays's AMGN Position: Q1 2026 in Review
Barclays reduced its Amgen (AMGN) stake by 20% in Q1 2026, selling an estimated $139M and leaving 1,529,613 shares worth $538M. The position accounts for 0.13% of the portfolio, ranked #119.
Barclays first reported a position in AMGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.23B in Q1 2024. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Barclays held 1,529,613 shares of Amgen worth $538M as of Q1 2026.
- Barclays sold 390,882 Amgen shares in Q1 2026, an estimated $139M.
- Amgen made up 0.13% of Barclays's portfolio in Q1 2026, its #119 holding.
- Barclays first reported a position in Amgen in Q2 2013 and has held it in 52 quarters since.
- Barclays's Amgen position peaked at $1.23B in Q1 2024.
- 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.